Psychiatric Medications
• Post-traumatic stress disorder (PTSD)
↑↑ role of psychological therapies with EMDR (eye movement desensitisation and reprocessing) First line SSRI: paroxetine Second line ANXIETY DISORDERS TCA: amitryptiline NASSA: mirtazapine
• All patie nts should be offered psychological interventions as a first line option or as an adjunct Third line to pharmacological therapy MAOI: phenelzine Self help materials DEPRESSION BT in groups or individually Anxiety management therapy: combination of education, relaxation and graded exposure
• Mild depression Psychodynamic psychotherapy Do not use antidepressants routinely
• If patient s present in an anxiety CRISIS they may require a short course of anxiolytic therapy to Offer psychological interventions: self-help materials, CBT, or counselling provide r apid response whilst longer-term treatment is being established Consider medication if: MAXIMUM OF 4 WEEKS’ ANXIOLYTIC THERAPY due to high risk of dependency
Past history of moderate/severe depression
Benzodiazepines: diazepam 2mg TDS, chlordiazepoxide 10mg TDS
Persistent subthreshold depressive symptoms (i.e. lasting over 2 years)
Az apirones: buspirone 5mg BD/TDS
Mild depression persists after psychological interventions
Sedative antihistamines: promethazine 25-50mg OD
• Moderate to severe depression
• Generalised anxiety disorder (GAD) First line First line SSRI: fluoxetine or citalopram SSRI: fluoxetine, citalopram, paroxetine, or sertraline Second line SNRI: venlafaxine or duloxetine NASSA: mirtazapine SARI: trazodone NARI: reboxetine or lofepramine Second line MAOI: moclobemide Third line (severe depression) Specialist SNRI: venlafaxine or duloxetine Clonidine (off-patent indication) TCA: clomipramine, imipramine or amitryptiline
• Panic disorder
• Refractory depression (failure to respond to 2 or more antidepressants) First line
Consider PRN propranolol if attacks are infrequent/predictable
Combinations of antidepressants e.g. SSRI + NASSA, SNRI + NASSA
SSRI: fluoxetine, citalopram or paroxetine NARI: reboxetine or lofepramine
Augment therapy with lithium or atypical antipsychotics
Second line TCA: clomipramine or imipramine Third line BIPOLAR DISORDER MAOI: phenelzine or moclobemide Specialist
• Acute manic episode (manic symptoms lasting >1 week) Clonidine (off-patent indication) First line
• Phobic disorder Atypical antipsychotics: olanzapine, risperidone or quetiapine First line Second line
Consider PRN propranolol for situational anxiety or predominating physical symptoms
Augment antipsychotics with lithium, sodium valproate, carbamazepine or lamotrigine SSRI: fluoxetine, citalopram or paroxetine
• Acute depressive episode (depressive symptoms lasting >2 weeks) Second line Antidepressants are not used routinely in bipolar disorder, as they increase risk of rebound TCA: clomipramine or imipramine
don’t prescribe them without antimanics
Third line First line MAOI: phenelzine or moclobemide Atypical antipsychotics: quetiapine, olanzapine in combination with fluoxetine
• Obsessive compulsive disorder (OCD) Antiepileptics: lamotrigine First line
• Long-term treatment (prevention of relapse through mood stabilisation) SSRI: paroxetine
Again, antidepressants aren’t used routinely Second line First line TCA: clomipramine Third line Second line MAOI: phenelzine or moclobemide
Either replace or augment lithium therapy with other drugs
Specialist Antiepileptics: sodium valproate, carbamazepine or lamotrigine Clonidine (off-patent indication) Atypical antipsychotics: quetiapine, olanzapine or aripiprazole Atypical antipsychotics e.g. olanzapine Laura Jayne Watson 2011
ADHD e psicofarmaci: bambini diversamente attivi In America ci sono 13 milioni di bambini che fanno uso di psicofarmaci come Ritalin e affini, e numeri simili si stanno raggiungendo in paesi come la Germania, l’Inghilterra e la Francia. E in Italia? Corriamo anche noi il rischio di avere tra pochi anni una generazione di giovani adulti cresciuta a psicofarmaci?
QUALCOMM INCORPORATED, Plaintiff-Appellant, v. BROADCOM CORPORATION, Defendant-Appellee. 2007-1545, 2008-1162 UNITED STATES COURT OF APPEALS FOR THE FEDERAL CIRCUIT 548 F.3d 1004 ; 2008 U.S. App. LEXIS 24749 ; 89 U.S.P.Q.2D (BNA) 1321 December 1, 2008, Decided SUBSEQUENT HISTORY: certiorari dismissed by Qualcomm Inc. v. Bradcom Corp., defendant-appellee. With him